For marketing authorization, the relationship between the USP, EP, and JP is best described as: Response:

Question

Options

• AMutually exclusive.
• BInterchangeable.
• CRegion-specific requirements.
• DIdentical across all regions.

• A
  7% (2)
• B
  4% (1)
• C
  79% (22)
• D
  11% (3)

Explanation

Option C is correct because the USP (United States Pharmacopeia), EP (European Pharmacopoeia), and JP (Japanese Pharmacopoeia) are official standards bodies tied to their respective regulatory regions - the FDA requires USP compliance in the US, the EMA relies on EP in Europe, and the PMDA references JP in Japan. Each pharmacopeia sets quality, purity, and testing standards tailored to its own regulatory framework and approved drug products.

Why the distractors are wrong:

• A (Mutually exclusive): They're not in conflict - a manufacturer can comply with multiple pharmacopeias simultaneously, and harmonization efforts (ICH Q4B) actively seek alignment between them.
• B (Interchangeable): While they overlap significantly, they are not freely substitutable; a regulator in one region will not automatically accept another pharmacopeia's monograph without review or recognition.
• D (Identical across all regions): Specific monographs, acceptance criteria, and testing methods can differ across the three - they are similar but not identical.

Memory tip: Think "region = regulation." Each pharmacopeia is a product of its home regulatory authority. USP = US/FDA, EP = EU/EMA, JP = Japan/PMDA. The name tells you the territory.

No community discussion yet for this question.